Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common arthritis drug tame a rare, fatal blood vessel disease?

NCT ID NCT06923072

Recruiting now Disease control Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether baricitinib, a drug already approved for arthritis, can help people with Kohlmeier-Degos (KD) disease that affects the brain and spine. KD causes inflammation and blood clots that damage small blood vessels, and there is currently no treatment. The trial will enroll 12 adults who will take baricitinib daily for 24 weeks, and researchers will use MRI scans to see if existing lesions stabilize and no new ones appear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KOHLMEIER-DEGOS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant atrophic papulosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEGOS DISEASE KOHLMEIER-DEGOS DISEASE MALIGNANT ATROPHIC PAPULOSIS PAPULOSIS, MALIGNANT ATROPHIC

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••